Challenge–dechallenge–rechallenge
Challenge–dechallenge–rechallenge (CDR) is a pharmacological testing method used to determine the causality of an adverse event or reaction to a drug. This method is particularly useful in clinical pharmacology and toxicology to assess whether a specific drug is responsible for an adverse reaction.
Overview
The CDR test involves three key steps:
- Challenge: Initially, the drug suspected of causing an adverse reaction is administered to the patient. The objective is to observe whether the adverse reaction occurs when the drug is introduced.
- Dechallenge: If an adverse reaction is observed during the challenge phase, the drug is then withdrawn or discontinued. This step is crucial to see if the adverse reaction subsides or disappears once the drug is no longer being administered.
- Rechallenge: In this final step, the drug is reintroduced to the patient after the symptoms have resolved from the dechallenge phase. A positive rechallenge is indicated if the adverse reaction reoccurs upon reintroduction of the drug.
Clinical Significance
The CDR test is a critical tool in clinical trials and pharmacovigilance for establishing a causal relationship between a drug and an adverse reaction. This method provides more concrete evidence compared to anecdotal reports, as it systematically tests and observes the effects of the drug in the same patient under controlled conditions.
Applications
CDR is widely used in:
- Drug development and regulatory affairs to provide evidence of drug safety.
- Clinical settings to diagnose drug allergies or intolerances.
- Legal and forensic investigations to establish liability in cases of drug-induced harm.
Limitations
While the CDR test is valuable, it has limitations:
- Ethical concerns arise, particularly in the rechallenge phase, if the adverse reaction is severe.
- The test is not suitable for drugs with long half-lives, where washout periods are impractical.
- There is a risk of severe reactions upon rechallenge, which requires careful consideration and ethical justification.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD